Find latest Myeloma videos
·
200+ videos
Unmet Medical Needs in Early MM Relapse
By
COR2ED The Heart of Medical Education
FEATURING
Elena Zamagni
By
COR2ED The Heart of Medical Education
FEATURING
Elena Zamagni
Although therapeutic advances in multiple myeloma have improved patient outcomes, this has generated a wide range of patient profiles at early relapse.
Dr Elena Zamagni summarises the unmet medical needs in earlier relapses in multiple myeloma including:
- The current treatment landscape and challenges
- Current guidelines and recommendations
- The need for new targets/therapies with different mechanisms of actions
Clinical takeaways:
- Current guidelines recommend lenalidomide-based treatment in the frontline setting - Non-transplant eligible patients may become anti-CD38 refractory after one prior line of therapy
- Although therapeutic advances in multiple myeloma have improved outcomes, this has generated a wide range of patient profiles at early relapse, many with substantial unmet needs
- There is a need for new targets/new drugs with different mechanisms of action
This is part 1 of a 3-part video series.
Watch part 2 to see Dr Fredrik Schjesvold focus on the importance of the MoA
Go to part 3 to see Dr Joseph Mikhael discuss current best practices in treating patients with multiple myeloma
Read more about the experts and download the accompanying slide sets on our website
Subscribe to the COR2ED YouTube channel to stay up-to-date with new medical education content as it’s released.
Come and find LYMPHOMA & MYELOMA CONNECT on social media
Follow us on X
Follow us on LinkedIn
This content is intended for healthcare professionals only. The medical experts in this video are expressing their own views and not those of COR2ED, supporters, or their institution.
This programme is supported by an Independent Medical Education Grant from Menarini Stemline Oncology.
This video was developed by cor2ed.com
Publication date: September 2024
Dr Elena Zamagni summarises the unmet medical needs in earlier relapses in multiple myeloma including:
- The current treatment landscape and challenges
- Current guidelines and recommendations
- The need for new targets/therapies with different mechanisms of actions
Clinical takeaways:
- Current guidelines recommend lenalidomide-based treatment in the frontline setting - Non-transplant eligible patients may become anti-CD38 refractory after one prior line of therapy
- Although therapeutic advances in multiple myeloma have improved outcomes, this has generated a wide range of patient profiles at early relapse, many with substantial unmet needs
- There is a need for new targets/new drugs with different mechanisms of action
This is part 1 of a 3-part video series.
Watch part 2 to see Dr Fredrik Schjesvold focus on the importance of the MoA
Go to part 3 to see Dr Joseph Mikhael discuss current best practices in treating patients with multiple myeloma
Read more about the experts and download the accompanying slide sets on our website
Subscribe to the COR2ED YouTube channel to stay up-to-date with new medical education content as it’s released.
Come and find LYMPHOMA & MYELOMA CONNECT on social media
Follow us on X
Follow us on LinkedIn
This content is intended for healthcare professionals only. The medical experts in this video are expressing their own views and not those of COR2ED, supporters, or their institution.
This programme is supported by an Independent Medical Education Grant from Menarini Stemline Oncology.
This video was developed by cor2ed.com
Publication date: September 2024
Comments 0
Login to view comments.
Click here to Login
